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Amenorrhea as the first manifestation of a 
steroid biosynthetic defect is rather unusual. The 
common forms of congenital adrenal hyperplasia are 
classic examples of steroid biosynthetic defects. Yet 
in genotypic females. this disorder is usually evident 
from birth because of virilization. Effective treatment 
usually ensues and amenorrhea is only a problem 
when control is inadequate. However. there are in­
dividuals whose disorder will be manifest for the tirst 
time in the postnatal or adult period. In addition. 
multiple other steroid defects have now been clearly 
delineated. Many of these individuals will have 
amenorrhea, virilization. or sexual ambiguities as 
part of the clinical picture. This paper will describe 
some of the more clearly delineated steroidal bio­
synthetic defects. Also, the clinical management or 
patients with postnatal onset of 21-hydroxylase defi­
ciency form of congenital adrenal hyperplasia will 
be discussed. 
Steroidogenesis. One can better appreciate the 
biochemical defects and clinical manifestations of 
these various steroid defects by having a rudimentary 
knowledge of the basic steroid pathways involved. To 
pinpoint the individual defects, it is helpful to recall 
the numbering sequen..:e of the carbon atoms of the 
steroid molecule as shown in Figure I. For the pur­
poses of this discussion, one can consider cholesterol 
as the basic substance from which steroids are de­
rived. It is at the point of its conversion to pregnenolone 
that tropic hormones have their effect; that is, ACTH 
• Presented by Dr. Williamson al the 46th Annual McGuire 
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for the adrenal cortex, and the gonadotropins for the 
gonads (Fig. 2). When circulating levels of glucocor­
ticoids or sex steroids reach sufficient levels for 
physiologic functions of the individual, the classic 
negative feedback mechanisms become operative so 
that further releasing hormones from the hypo­
thalamus are held in abeyance, and the specific tropic 
hormones from the pituitary are not released until 
there is further need for additional hormones. 
In the biosynthetic defects discussed here, the 
steroid end products necessary for physiological 
function are not formed in optimum amounts. This 
triggers release of releasing factors from the 
hypothalamus which in turn causes secretion of the 
tropic hormones from the pituitary. Next, stimula­
tion of the target glands (adrenal and/or gonads) 
leads to excessive intermediate products being 
elaborated up to the point of the defect. Clinical 
manifestations of these disorders are due to a 
deficiency of a normal end product, an excess of in­
termediate substances with the possible peripheral 
conversion to other hormones, or usually both. In 
defects involving steps early in the biosynthetic 
pathways, the adrenals and gonads are involved. Ab­
normalities occurring later in the order of flow usual­
ly involve only one gland or the other. Important sex 
steroid precursors and weak androgens may be 
formed by the adrenal and converted to more potent 
androgens and even estrogens in certain of these dis­
orders. Such conversions apparently occur in the liver 
and skin and possibly other tissues. However, the 
gonads do not form glucocorticoids. 
Specific Defects. Brief descriptions of biosyn­
thetic defects will be outlined starting at the more 
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reported two patients with this disorder and collected 
five additional cases. All seven died before the eighth 
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Fig. I-Numbering sequence for the first 21 carbon atoms in 
steroid nomenclature. Useful in locating biosynthetic steroid 
defects described in this paper. 
primitive, or early, stages of steroid biosynthesis 
and proceeding to later-stage defects. Accordingly, 
the order of presentation bears no relationship to 
relative frequency or importance of these dis­
orders. 
C-20 block with /ipoid adrenal hyperplasia 
(Desmolase deficiency CAH) (Fig. 3). Being unable 
to convert cholesterol to pregnenolone, af
f
ected in­
dividuals lack life-sustaining steroids; hence the dis­
order is fatal. The condition is of interest lo the 
gynecologist in that it supports Jost's work regarding 
virilization of the genital tracts. Being a primitive 
(early) defect, it involves steroidogenesis in the 
gonads as well as in the adrenals. The fetal testes are 
unable to form adequate androgens to virilize the 
genitalia fully, leading to genital ambiguity in genetic 
males. This is in contradistinction to the findings in 
the more common 21- and also 11-hydroxylase forms 
of congenital adrenal hyperplasia where genetic 
females are often born with ambiguous genitals. 
Cholesterol accumulates in the adrenal of affected 
individuals; hence the designation "lipoid." Theo­
retically, the treatment would be the administra­
tion of glucocorticoids and mineralocorticoids with 
the addition of appropriate sex steroids at the time of 
pubescence. Prader, Gurtner, and Siebenmann ( I, 2) 
month of life with adrenal insufficiency even though 
treatment with gluco- and mineralocorticoids had 
been employed. Although other steroid abnormalities 
may be present, it is probable that the main defect is 
in the transformation of cholesterol to pregnenolone 
(3). Early fatalities preclude this form of CAH in the 
differential diagnosis of amenorrhea, though ul-
timately a mild form of the defect with survival might 
be anticipated. 
Three (3-hydroxysteroid dehydrogenase deficiency 
(Fig. 4). Being unable to convert pregnenolone to 
progesterone, these individuals present with many of 
the features of the previously described desmolase 
deficiency. Salt loss has been a prominent feature of 
the adrenal insufficiency with the result that fatalities 
are usual. Inadequate testosterone leads to am­
biguous genitals in genetic males whereas mild 
virilization of affected females has been attributed to 
testosterone being formed from increased amounts 
of dehydroepiandrosterone (DHA) and other pre­
cursors. Since it is a primitive defect, gonadal 
steroidogenesis is also affected. In Bongiovanni's 
series (4), three females out of a total of six in­
dividuals with this form of CAH were surviving. He 
postulated a partial defect as did Kenny and his co­
workers (5). The latter authors also showed in­
creasing 3(3-hydroxysteroid dehydrogenase activity 
with increasing age. Steroid excretion patterns in 
these patients would suggest the development of 
alternate pathways which allow for survival of some 
infants. The presence of pregnenetetrol (with a 
hydroxyl group at C 21) suggests the ability of 17-
hydroxylase and 21-hydroxylase to act on this 
"primitive" molecule (6). This compound is not ex­
creted in increased amounts in the usual 21-
hydroxylase deficiency (7). Since this enzyme also 
plays an important part in the gonadal biosynthesis 
of sex hormones (6), its absence would necessitate 
substitutional sex-hormone therapy at pubescence. 
Obviously sterility can be anticipated. 
Seventeen cx-hydroxylase defect (Biglieri syn­
drome) (8) (Fig. 5). This being a primitive block, 
the gonads and adrenals are involved. Absence of 
adequate sex steroids leads to hypogonadism and 
elevated gonadotropins. The elevated levels of desoxy­
corticosterone (DOC) and. corticosterone lead to 
hypokalemic alkalosis and hypertension, thus turning 
off the renin-angiotensin mechanism with resultant 
low or absent aldoslerone. This defect is clinically ex-
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Fig. 2-A bbreviated steroid flow sheet of major steroids produced in the hum,111. M incralrn.:onicoids arc regulated by a mechanism involv­
ing osmolar and presser receptors and in turn the renin-angiotensin mt.:chani:-.m and only to a minor degree by ACTH. The glucocorticoid 
(cortisol) plasma levels are modulated by negative feedback influence or the I I-hydroxyl group on the hypothalamus and in turn its releasing 
factor for ACTH. The major sex steroids. testosterone and the estrogen,. typified by cstradiol. arc produced from adrenal DHA and 
androstenedione in tissues peripheral to the adrenal su...:h as the liver and the �kin. Some degradation products of major steroids 
are pointed out by small arrows beneath the individual steroids. 
pressed in the genetic female by hypertension and the 
absence of puberty. In addition to the elevated 
gonadotropins, blood progesterone is high. In the 
genetic male, ambiguous genitalia and absence of 
puberty result from the inability to make either an­
drogens or estrogens; hence it is a cause of male 
pseudohermaphroditism (9). This syndrome in 
genetic females is similar to the feminizing testicular 
syndrome in the absence of secondary sex hair, bu! 
differs in that breast development is absent and 
hypertension is present. The treatment in females is 
adequate substitutional therapy with glucocorticoids. 
Preference is given to one without significant 
mineralocorticoid activity; for example, prednisone. 
Addition of sex steroids at pubescence is indicated, 
but infertility can be expected. It would appear that 
these patients could be monitored for effectiveness of 
therapy by the measurement of plasma progesterone. 
Simple uiri/izing congeniwl adrenal hyperplasia 
(mild 21-hydroxylase defect) (Fig. 6). Being unable to 
form optimal amounts of cortisol and corticosterone, 
these individuals exhibit augmented ACTH produc­
tion which leads to shunting towards the androgen 
pathway and ultimate virilization. Aldosterone and 
cortisol (hydrocortisone) are formed in suboptimal 
amounts so tha< overt adrenal insufficiency may not 
be necessarily manifes< (10, 11). The majority of fe­
male patients will have exhibited considerable evi-
18 
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in utero. 
dence of virilization and usually sexual ambiguity at 
birth. leading to prompt diagnosis and treat111ent. In 
the afTected male. however. the external genitalia 
are nor111al and the diagnosis of CAH is therefore 
less obvious. This doubtless accounts for the pre­
do111inance of the disorder in females: that is. 111ales 
may die of undiagnosed hypoadrenalis111. 
Diagnosis and treatment depend largely on sup­
pressibility of the hyperactive hypothalamic-pituitary­
adrenal axis by exogenous administration or 
11-hydroxylated glucocorticoids. Androgens are elt:­
vated in plasma and urine. Estrogen excretion may 
be elevated in these individuals ( 12. 13 ). Such es-
trogenic activity is not clinically manifest. Pre­
sumably. the excessive androgens effectively over­
ride the estrogenic activity. Most investigators have 
held that urinary gonadotropins are suppressed by 
the excessive androgens ( 13. 14). However. Stevens 
and Goldzieher ( 15) found detectable and often adult 
levels of gonadotropins in 4 of 5 children with 
CA H and variable levels in adults. Steroid suppressive 
therapy led to a fall of FSH in 3 of6 patients whereas 
LH was unchanged in 5 and rose in 2. suggesting that 
co111pensatory pituitary hyperactivity in CAH is not 
limited to the pituitary adrenal mechanism but has 
repercussions in gonadotropin regulation as well. In 
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any event. once adequate suppressive therapy is in­
stituted. postpubertal females rapidly feminize and 
become ovulatory. 
Diagnosis can be suspected on the basis or 
baseline urinary 17-ketosteroids ( 17-KS). Normal 
adult females ordinarily have values between 2 and 12 
mg/24 hours. Patients with obesity. stress situations. 
essential and familial hirsutism or Stein-Leventhal 
syndro111e may have levels to 25 or even 30 mg/24 
hours whereas patients with CAH usually will have 
baseline values on the order or 50 111g/24 hours. 
Patients with adrenal adenomas ordinarily will have 
values of approximately 100 mg. and patients with 
virilizing adrenal carcinomas will have values or 200 
0 " 
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111g or up. The degradation 111etabolite of 17 hydroxy­
progesterone ( I 70H-P). pregnanetriol, was found to 
be elevated in the urine of these patients and has been 
used for years to conf-irm the diagnosis and to 
monitor therapy. Most laboratories report normal 
values in adult females to be 4 mg or less per 24 
hours. Patients with CAH have values from modestly 
above 4 mg up to manyfold this level. The sup­
pressibility of this steroid as well as 17-KS by 2 mg of 
dexamethasone every 6 hours for two days proves the 
ACTH dependence of the disorder and differentiates 
it from the autonomous virilizing adenomas and car­
cinomas ( 16). However. it appears that pregnanetriol 
is not a primary intermediate in the formation of an-
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drogens (17) suggesting that the major pathway is 
through DHA and androstendione. Although 170H-P 
has been known to be elevated in this disorder for 
years (18). its measurement as a practical matter has 
been of more recent vintage ( 19, 20). The bother and 
inaccuracy of collection of 24-hour urine specimens 
for steroid assays has led to the measurement or 
plasma I 70H-P, progesterone, and testosterone in 
diagnosing and monitoring these patients. Lippe and 
co-workers point out multiple factors that may affect 
serum steroid determinations (21 ): hence they suggest 
that where virilization is a prominent feature in 
amenorrheic women, long-term adrenal suppression 
tests with measurement of several plasma steroids 
(for example. I 70H-P and testosterone) be utilized. 
Normal adult patients ordinarily have plasma I 70H-P 
levels of up to 200-400 ng% whereas patients with 
CA H and blocks of C-21 or C-11 hydroxylation will 
have levels severalfold that amount when untreated 
or if out of control (for example. 1-4 µg%) (19). 
A subvariant of the mild 21-hydroxylase de­
ficiency is that of the postnatal onset of the dis­
order. Sporadic cases have been reported (22. 23. 24) 
and described. It would appear that these individuals 
have a milder form of the disorder which becomes 
manifest only upon their being stressed. 
Other subvariants of the 21-hydroxylation 
deficiency include periodic fever in association with 
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elevated plasma etiocholanolone (25) and "late" 
sodium Joss (26). Hypoglycemia probably is not a 
separate subvariant but a manifestation of hypo­
adrenalism. 
Severe 21-hydroxylase defect (salt-losing con­
genital adrenal hyperplasia) (Fig. 7). This variant 
of the 21-hydroxylase defect is more complete so 
that a deficiency of mineralocorticoids including 
aldosterone exists. Shunting to the androgenic 
pathway is also present leading to virilization. The 
defect. being of more profound degree, leads to even 
higher ACTH levels than in the simple virilization 
syndrome so that hyperpigmentation may ensue and 
indeed has been used as a clinical sign in addition to 
II 
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steroid assays in the monitoring of therapy. 
Diagnosis is the same as with the mild form, but 
treatment differs. In addition to suppressive therapy 
with a glucocorticoid, a mineralocorticoid and often 
salt supplementation are necessary. It has been 
suggested that different 21-hydroxylation defects may 
exist in the salt losers as opposed to the nonsalt losers 
(27). 
Eleven-hydroxylase deficiency (hypertensive con­
genital adrenal hyperplasia) (Fig. 8). In addition to the 
shunting along the androgenic metabolic pathway as 
in the 21-hydroxylase defects, the mineralocorticoid, 
DOC, accumulates, leading to salt retention and 
hypertension. These patients also frequently pigment 
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precocity and pseudohermaphroditism in female infants. 
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Fig. 7-Severe 21-hydroxylase defect. Virilization findings similar to the mild form but additionally salt loss occurs due to the mineralocor­
ticoid deficiency including aldosterone. 
from the excessive ACTH activity. Clinically, these 
patients present as the 11-hydroxylase patients except 
for hypertension and salt retention. Diagnosis can 
be suspected on the basis of hypertension. Biochemi­
cal confirmation is by the finding of elevated levels of 
tetrahydro-S (the degradation product of 11-desoxy­
cortisol) in the urine. More specific radioimmuno­
assays for DOC and 11-desoxycortisol may simplify 
diagnosis in the future. 
Late onset of this disorder has also been 
reported (28, 29). Zachmann and co-workers exten­
sively studied an infant girl with an 11-hydroxylase 
deficiency who was normotensive and had normal 
levels of DOC though compound S was excessively 
high. This suggested to them a selected inhibition of 
the 11/3-hydroxylation of I 7a-hydroxylated steroids 
(30). 
Eigh1een-hydroxy/ase dehydrogenase defec1 (Fig. 9). 
Ulick (31) described this disorder accompanied by 
low aldosterone resulting in low serum sodium. hi�h 
potassium, dehydration, hypotension, high renin ac­
tivity, and elevated levels of hydroxycorticosterone. 
This disorder should not enter into the differential 
diagnosis of amenorrhea and the virilizing congenital 
adrenal hyperplasias. 
Seven1ee11 /3-hydroxysferoid dehydrogenase de­
feel (deficienf 1es1icu/ar J 7-ke1os1eroid reduc1ase ac­
livity) (Fig. 10). Goebelsmann and co-workers (32) 
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described a 46-year-old married phenotypic female 
with clitoral enlargement, hirsutism, breast develop­
ment, and a blind vaginal pouch. Chromosomal 
karyotype was 46 X Y. Abdominal testes were re­
moved. Prior to operation, testosterone was at low 
normal male levels, though considerably above female 
levels. Urinary 17-KS were 33 mg/24 hours. The find­
ing of androstenedione of 1.02 µg/ 100 ml (being ten­
fold above normal male levels) suggested testicular 
I 7JJ-hydroxysteroid dehydrogenase deficiency. More 
recently, Givens and associates (33) described two 
additional patients (sisters) with primary amenor­
rhea. hirsutism. clitoral enlargement, 46 XY karyo­
type. but lacking breast development. They, too, 
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found grossly elevated androstenedione levels along 
with elevated urinary 17-KS and plasma estrone, but 
subnormal amounts of testosterone and estradiol. In 
vitro incubation of testicular tissue from their sec­
ond case confirmed a partial defect in testicular 17-
KS reductase activity and documented increased 3JJ­
hydroxysteroid dehydrogenase activity. They felt that 
failure of breast development was probably due to 
lower estrogen levels than in previously reported 
cases. Accordingly. when one finds elevated 17-KS in 
an amenorrheic individual, further delineation or 
the defect by steroid biochemical assays seems 
warranted. Indeed, such investigations may show the 
Reifenstein syndrome as well as other forms of male 
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Fig. 8-Eleven-hydroxylase defect. Virilization due lO shunting ol' adrenal precursors to androgenic pathway. Hypertension results lrom 
accumulation of mineralocorticoids-principally desoxycorticostcronc. 
24 WILLIAMSON AND MATHUR: DEFECTS IN STEROID BIOSYNTHESIS 
0 " 
CH,-C-5-CoA 
"Acetate" 
"� 
CHOLESTEROL 
9H20H 
,# 
CH s 
C•O 
ALDOSTERO
� 
CHzO� 
, 
C,H20H I CHs t C•O 
,,oSD 
3-/3-ol-deH 
� 
21-0H 
� . � 
ISOMERASE Pre9nonediol 
0 h 
-•� � 
H
�rtS 
OCC( OCC( 
CORTICOSTERONE 
(CO. B K ) 
q HzOH 
C•O 
PREGNENOLONE 
17- 0H I qH , 
'f C• O 
PROGESTERONf 
I qH , t C•O 
OH 
DESOXYCORTICOSTERONE 
(DOC) 
C1H20H 
C•
�OH 
_.m
OH
� 
HO(:() 
� 
netriol -- o�
°
" 
17-0H-PREGNENOLONE 
DH A 
(17-KS) 
' 
0 
17-0H-PROGESTERONE 
i 0 
--6·-� ,\, 
(17-KS) 
1 l·DESOXYCORTISOL 
(CO.SR) 
OH 
_,ffi 
0� 
TESTOSTERONE 
CORTISOL 
(CO. FK) 
OH 
,,oSP 
ESTRADIOL 
Fig. 9-Dercct or 18-hydroxylase dehydrogenase. Aldostcronc deficit lead, tu dccrca,cd plasma sodium. high potassium. dehydration. 
hypolension. and high renin activity. No direct gynecologic c:ndocrinop,llh) a:-.:-.cH.:iatiun. 
pseudohermaphroditism to be due to this disorder of 
steroid biosynthesis. 
Stein-Leventhal syndrome (Fig. 11 ). Early 
workers dealing with in vitro studies showed an ac­
cumulation of DHA and testosterone in incubation 
studies on ovarian tissue from patients with this syn­
drome. These studies suggested a partial defect in 
the aromatizing enzyme to convert testosterone 
to estradiol as well as an inadequacy of 3/3-ol 
dehydrogenase activity. However, such observations 
were not interpreted to imply the uniform existence 
of invariable, all-or-none enzyme defects in the 
polycystic ovarian tissue (34). Accumulating evidence 
would suggest, however. that the issue is much more 
complex. Probably there are patients now classed 
with this syndrome whose disease primarily resides in 
the adrenal cortex. others who have primarily an 
ovarian defect: but the majority have a defect in 
hypothalamic function. Accordingly. it is felt that 
there is no such neat demonstration of a consistent 
biochemical defect as outlined in Figure 11 in spite of 
early works suggesting such. 
Case Presentations. Post-pubertal simple viriliza­
tion. Patient M.S.H .. Duke Unit #5-59154 (Fig. 12). 
A 17-year-old female was seen on referral November 
I, I 961. with defeminization. Menarche was at 11 
years with regular menses for two years. At age 13. 
the patient had mumps and measles during a two-
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week period. Infrequent and scant menses. averaging 
one per year followed. Acne and hirsutism steadily 
progressed after age 11. Loss of scalp hair had 
progressed for 5 months. Patient was said to be the 
product of a normal term delivery, though she was 
adopted. Pertinent laboratory findings are noted in 
Table I. Two rest days intervened between the 
ACTH. metapyrone, and dexamethasone tests. Sup­
pressive therapy was started, and the patient had an 
ovulatory spontaneous menstrual period 6 weeks 
later proved by endometrial biopsy. She was mar­
ried, and while on suppressive therapy. delivered 
,pontaneously on January I, 196 7. under pudenda! 
,lock anesthesia, a 5 lb. 8 oz. normal male infant 
CH, 
I 
C=O 
and on November 21, 1968, a 6 lb. 15 oz. normal 
female infant by Dr. William A. Peters. Her pelvis 
was normal by x-ray pelvimetry. During each de­
livery, the patient was supported by parenteral 
hydrocortisone, and her oral glucocorticoid was 
doubled then gradually tapered to maintenance level 
during the immediate puerperium. In that the 
patient appeared so normal and was cycling spon­
taneously, gl ucocorticoid therapy was discontinued 
in September 1969. She has continued to have 
cyclic menses without evidence of virilization. Dur­
ing the past year. her urinary 17-KS were 13.7 
mg/24 hrs on two occasions, and her 17-hydroxy­
corticosteroids (I 70H-CS) 2.9 and 4.3 mg/24 hours. 
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Fig. 10-Defect of 17/3-hydroxysteroid dehydrogenase . Extremely rare steroid defect where androstenedione incre
.
ased some ten
fo
ld over 
normal levels while achieving low normal testosterone. Reported in male pseudohermaphrodites. hence a cons,derauon in d1fferent1al 
diagnosis from common forms of CAH. 
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Co111111e111. Postnatal virilization of the female is 
more commonly due to an autonomous tumor or in­
gestion of hormones than due to the postnatal (ac­
quired) form of congenital adrenal hyperplasia. 
However. ready suppressibility of this patient's 
greatly-elevated abnormal steroids bespeaks the 
nature of her disorder. Since her onset occurred after 
most. if not full. statural growth had been achieved. 
she was not stunted. nor was her pelvic capacity com­
promised. Accordingly. delivery was spontaneous. 
Her children have been assessed for the possibility of 
congenital adrenal hyperplasia. and this has been 
ruled out. The chances of offspring having the dis­
order are remote. since the prevalence of the gene for 
the disorder is on the order of I in 128 for heter­
ozygotes and I in 67.000 for the overt disease (35). 
However. the frequency will be on the increase in that 
affected individuals with proper treatment will no 
longer be sterile (36). This patient is remarkable in 
that she has remained apparently normal for a pro­
tracted period of time off of therapy in spite of a 
severe abnormality of steroidogenesis when first diag­
nosed. Her 17-KS are now upper limits of normal and 
her I 70H-CS are low bespeaking the fact that she 
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probably is just minimally compensated. However. 
she has undergone the stress of rearing two small chil­
dren and moving to Europe without decompensating. 
Accordingly. our original hypothesis or decompensa­
tion due to psychologic stress of adolescence may bt: 
questioned (37). 
Postnatal simple virilization. Patient K.S.S .. Unit 
# 61682 (Fig. 13). A 13-year-old white female was 
seen January 18. 1963. because or "virilizing syn­
drome." She was born prematurely. Development 
was normal until age 4 when pubic and axillary hair 
became apparent. Her 17-KS were elevated. and 
glucocorticoid therapy was given elsewhere for two 
years. but discontinued by the mother when 
Cushingoid features developed. These rapidly dis­
appeared. but were followed by progressive hir­
sutism. One brother had prostatic hypertrophy 
diagnosed at age 19. 
Suppressive therapy was started January 23. 
1963. and the patient was hospitalized elsewhere 
April 3. 1963. with right lower quadrant abdominal 
pain. Fifteen days later. menarche occurred and was 
followed by regular menses and rapid budding or 
breasts. Hirsutism gradually decreased. but her voice 
remained unchanged. Significant laboratory data are 
shown in Table I. Iliac crests were fused on the ab­
dominal film. With her last menstrual period in 
May 1967. and after an adequate trial of labor. 
patient was delivered by cesarean on February 5. 
1968. of a 5 lb. 7 oz. normal female. Opera-
Fig. 12-Paticnt M .S. H .. #F-59154. Normal r eminine contour and 
cndocrint: mc.!asurements existed with comcdones and racial hir­
,uti>rn. B.P. 120/70. Weight 61 kg. 
TABLE I 
Urinar� S11.:ruiJ .... 
Patient Age Therapy 17-KS 17-0H-CS 17-Kctogcnic Prcgn..inetriol 
M.S.H. 17 None 82.8 I 1.-l I). 7 9.7 
ACTH Gel 40 U IM 
q. 12hrs. X 3days 16-l.7 .ll.O I )6.6 2-l.9 
Mctapyronc 500 mg 77-l -l 1.8 128.0 -13.2 
q. 4 hrs. X 2 days 
Dexamethasone -11.8 1.-l 9.8 2.9 
0.5 mg. q. 6 hrs. X 2 days 
Dexamethasonc H 0 3.6 0.5 
2 mg. 4. 6 hrs. X 2 days 
K.S. 13 None 40.1 71.3 
Dexamethasone I 8.3 107.8 
0.5 mg q. 6 hrs. X 2 days 
Dexamethasonc 7.6 .ll.-l 
0.5 mg q. 6 hrs. X 2 days 
Dexamcthasone 5. 7 2.7 11.6 1.-l 
2 mg. q. 6 hrs. X 2 days 
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Fig. 13-Paticnl K.S.S .. # 6168�. ShO\\:,, :-.tunlcd grtl\\th. L.11..:ial hir­
sutism. and android c:-.cu1chcon. Chc:,,t \\a:,, :,,havcd prior to 
photograph� i'vl usck hypcrtroph� \\ <h pn::-.cnt and brca:-.t develop­
ment ab:-.cnt. Voice \\a:,, baritone. B.P. 150190. \\ 1:ight 55.5 !..g. 
Hcighl 152 cm. Sr,an 151 cm. LO\\Cr :-.cgmcnt 76 cm. 
tion was necessary due to a moderately con­
tracted pelvis of somewhat android configuration. 
The patient has been maintained on prednisone 5 
mg at bedtime. She continues to cycle normally. Her 
plasma I 70H-P of 216 ngo/,. plasma progesterone 
1.4 µg0!c in luteal phase with plasma estradiol 20.3 
ng%. suggest ovulation. However, her plasma tes­
tosterone persisted in the range from 80 to 120 
ng% bespeaking continuing excessive testosterone 
production. Accordingly. an additional 2.5 mg of 
prednisone is being added in the morning. 
Co111111e111. Failure to continue glucocorticoid 
therapy as prescribed by her physician led to 
premature closure of this patient's epiphyses and ul-
timate stunting from excessive sex steroids. In turn, 
this probably necessitated delivery by cesarean 
because of cephalo-pelvic disproportion. In the past, 
some patients with adrenal hyperplasia who could 
not tolerate steroid therapy have been subjected to 
adrenalectomy. However, such surgical therapy is no 
longer warranted, for proper monitoring should be 
achievable so that the disease can be brought under 
control without significant side effects from the 
medication. Hayek and associates have suggested the 
single dose of a long-acting suppressive agent at mid­
night for therapy of this disorder with good results: 
hence simplifying therapy (38). Such therapy is 
appealing and rational. However. one must use a fair­
ly long-acting steroid: therefore. oral hydrocortisone, 
the naturally occurring hormone that is missing, can 
not be utilized. Problems persist in such patients as 
this who have their sleep-wake patterns altered by 
work habits (she is a telephone operator working 
swing shifts). This may account for the need for an ad­
ditional a.111. dose. Reversibility of some signs of 
virilization occur (the patient has lost much body 
hair. though some facial shaving is still necessary). 
Rapid feminization as shown by breast development 
and ovulatory menses is to be expected once adequate 
therapy is instituted. Her hospitalizaiion was for 
suspected appendicitis. but the pain was apparently 
mittelschmerz. since she had her menarche two weeks 
later. Clitoromegaly and deep voice have persisted in 
this patient. since such changes. once they occur. do 
not reverse. Contraception in this patient. as well as 
in the first, is by intrauterine device. Estrogen­
containing oral contraceptives should be avoided 
in as much as they confound steroid monitoring of 
such patients by altering steroid binding proteins. 
This patient was found to be hypertensive when 
initially seen. raising the question of a possible 11-
hydroxylase block. However. measurement of 
tetrohydro-S showed no significant amounts of this in 
the urine. Prolonged hypertension following cessa­
tion of desoxycorticosterone therapy in CAH has 
been reported (39): however. we feel that this is 
highly unlikely in this patient. since initial therapy 
had been discontinued for almost a decade before 
she was found hypertensive. 
Pa1ie111 L. 0. T., Uni/ # 235684-5. A 38-year-old 
nulliparous obstetrical nurse was seen on referral 
because of inadequate control of adrenal hyperplasia 
while laking divided doses during the day. Some 
evidence of virilization probably was present at birth 
(clitoromegaly). though hirsutism did not become 
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manifest until after age 5. In 1954, the patient 
elsewhere underwent vaginoplasty, abdominal ex­
ploration, and clitoridectomy with the findings or 
follicular cyst of the ovary with occasional ova and a 
hypertrophic clitoris (5 cm.). The adrenals were 
thought normal to palpation. The patient was em­
pirically treated with Premarin® and thyroid and 
had withdrawal bleeding. All therapy was discon­
tinued in 1964, and she had spontaneous regular 
menses for one year with flow lasting 3-5 days and on 
occasion had associated cramping. Her baseline 17-
KS were 51 mg. rising to 109 with ACTH and sup­
pressing to 13.4 mg. with Decadron®. She was dis­
charged on 25 mg. cortisone per day and was later 
changed to prednisone. However, she was seen on 
referral, and her urinary pregnanetriol was 31.5 mg/ 
24 hrs. She was shaving twice daily. The patient was 
working swing shifts as a registered nurse. She was 
advised to take 5 mg. prednisone before going to bed 
and 2.5 on arising and an additional 2.5 mg during 
the day if necessary. Since institution of this therapy. 
her plasma testosterone has ranged from 16 to 28 
ng% with concomitant loss of chest and arm hair. 
though facial shaving is still needed. Her plasma 
estradiol has been between 2 and 43 ng%, though 
she has remained anovulatory while cycling. as 
shown by plasma progesterones repeatedly less than 
400 ng%. Her I 70H-P has ranged from 118 to 
496 ng%. 
Comment. Patients working swing shifts can ex­
perience considerable difficulty in controlling their 
excessive androgen production since the ACTH surge 
may come at a time when they are not receiving their 
larger dose of suppressive steroid. Also, changing 
shifts alter diurnal variation and may in itself be a 
stressful situation causing further decompensation. If 
even suppression is not obtained by giving a dose 
prior to anticipated ACTH surge, consideration of 
longer-acting injectable therapy such as utilized in in­
fants may be considered. Neither this patient, nor our 
patient undergoing cesarean, had evidence of 
classical Stein-Leventhal type ovaries, although CAH 
has been noted associated with polycystic ovaries 
(40). The thickened capsules in such patients have 
been attributed to excessive androgens. 
Patient P.B., Unit # 233484-2. A 23-year-old 
gravida II, para I, abortus O had menarche at age 12 
and cyclic menses until age 16 when she started skip­
ping menses. At age 17, she had ovarian wedge resec­
tions elsewhere with diagnosis of Stein-Leventhal 
syndrome. However, menses did not resume. She was 
seen by another physician who treated her with pred­
nisone. Menses then resumed, and the patient spon­
taneously achieved a pregnancy only to have mid­
trimester loss with prolapsed cord, intrapartum 
death, and delivery by cesarean. On physical exami­
nation, the patient had considerable facial hirsutism, 
modest clitoromegaly, but normal size ovaries. 
The patient was again studied off therapy with ele­
vated l 70H-P of 4.4 µg%. Her plasma progesterone 
was 132 ng%. With adequate suppression, plasma 
progesterone rose to 1.7 µg% (ovulatory level) and 
I 70H-P fell to 160 ng% (normal). The patient spon­
taneously resumed menses and became pregnant with 
last menstrual period November 11, 1974. On Janu­
ary 8. 1975. continuing the same dose of 5 mg 
prednisone at bedtime, her plasma testosterone was 
80 and plasma I 70H-P 137 ng%, and her plasma 
progesterone was greater than 1.6 µg%. 
Comment. Patients with congenital adrenal 
hyperplasia being adequately treated will be unable 
to have plasma or urinary estriols as an index of fetal 
well-being in as much as these steroids cross the 
placental barrier and suppress fetal-adrenal ac­
tivity-a most important source of precursors for 
pregnancy estriol. Differential suppression tests 
should be able to delineate patients with primarily 
ovarian disorders as opposed to those with primarily 
adrenal disorders and prevent unnecessary wedge 
resections in the future. 
Patient L.H.. Unit # 235525-8. A 27-year-old 
patient was seen in consultation because she had 
developed Cushingoid features as a result of being on 
prednisone for persistent amenorrhea. Menarche was 
at age 12 with an average of one cycle per year until 
age 18 when she was placed on oral contraceptives 
with regular withdrawal bleeding for three years. 
Upon discontinuance, the patient remained amenor­
rheic for one year when she was seen by a gyne­
cologist and had bilateral wedge resection of ovaries. 
She remained amenorrheic for another year except 
for scant spotting on rare occasion. The patient 
was admitted to another university center and under­
went dexamethasone suppression test with 17-KS, 
suppressing from 21 mg/24 hours to 6 mg on the 
first day of high-dose dexamethasone. She also had 
adrenal and ovarian vein catheterization, showing 
adrenal venous plasma testosterones quite elevated 
with some elevation of ovarian and peripheral 
values. She was placed on prednisone 10 mg every 
other day with spontaneous menses occurring ap­
proximately every 6-7 weeks. She then relapsed into 
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amenorrhea. Medication was discontinued for retest­
ing. and after one month off of therapy. her 
plasma I 70H-P was 1.8 µgo/o (approximately five 
to tenfold the normal values) with plasma testoster­
one 79 ng% (upper limits of normal for adult 
females in our laboratory are 60 ng%). plasma 
cortisol 10 µgo/o at 8 a.m .. plasma estradiol 24.1 
ng% (normal proliferative phase value), plasma 
progesterone 94.5 ng% (anovulatory value). On 
suppressive therapy. I 70H-P fell to 165 ng%, tes­
tosterone was 71 ng%. and plasma estradiol re­
mained at 22.9 ng% with progesterone 78 ng%. 
Stimulation with Clomid®. escalating doses to a 
maximum of 150 mg/day times five days. indicates 
the patient remains anovulatory with progesterone 
50.5 ng%. plasma estradiol 24 ng%. while 170H-P 
has remained 112 to 216 ng% during the time she 
is being maintained on p.m. suppressive prednisone. 
Commenl. This patient with a mild form of 21-
hydroxylation defect with first manifestations in post­
natal period did not achieve smooth suppression with 
alternate-day therapy. Even though nighttime 
therapy has brought about normalization of I 70H-P 
and near normal values of plasma testosterone. she 
remains anovulatory and unresponsive to Clomid"" 
at this time. In this patient, the elevation of 170H-P 
in the plasma out of proportion to the progesterone 
would indicate that her primary pathway to I 70H-P 
is through 17-hydroxy-pregnenolone rather than 
through progesterone. Also. findings would suggest 
that even though near-optimal biochemical control of 
the disorder can be achieved. fertility does not 
automatically ensue. She probably needs further sup­
pressive therapy. If optimum control is then achieved 
as shown by normal plasma testosterone. I 70H-P. 
and urinary 17-KS. then a search for other causes or 
amenorrhea are warranted, for they can be subject to 
such disorders as hypothalamic amenorrhea. 
Patieni J. L., Unit # 161059. An I I-year-old 
patient was seen in consultation after she had seen a 
group movie at school on sexual development in 
which a photograph of abnormal external genitalia 
was shown. She persisted in telling her teacher that 
she had such abnormal genitalia. Although "show 
and tell" in its fullest sense did not occur, this ex­
perience led to her being referred where the disorder 
was well characterized. She is now on suppressive 
therapy. 
Comment. Clitoromegaly of this degree, had it 
been present at birth, surely would have been 
recognized, though possibly some physicians may 
attempt to downplay its importance. However, the 
clinical course of this patient, that is, the onset of 
hirsutism and facial acne just prior to her evalua­
tion. would suggest postnatal onset of her disorder. 
Patient C. G., Unit # 172230-/. A 20-year-old 
patient had onset of virilization at age 11, and the 
diagnosis of congenital adrenal hyperplasia was made 
at a medical university well known for its large series 
of congenital adrenal hyperplasia patients. Initial 
attempts to control her here by continuing cortisone 
acetate which had been instituted elsewhere failed, 
and she was switched to prednisone in 1970. taking 
2.5 mg every eight hours. However, when seen in 
February. 1974, her 170H-P was greater than 1.4 
µgo/o. and her plasma progesterone greater than 1.6 
µgo/o. with plasma testosterone 72 ng%. She was 
anovulatory as shown by endometrial biopsy and 
basal body temperature charts. Five mg. of pred­
nisone at bedtime still failed to achieve suppression 
with plasma I 70H-P of 3.7 µgo/o, therefore, pred­
nisone has been increased to 7 .5 mg/day while sterili­
ty investigation is being pursued. 
Discussion. Differential diagnosis of congenital 
adrenal hyperplasia includes disorders of adrenal and 
gonadal origin. Rarely are such entities as Morgagni­
Stewart-Morel syndrome or Achard-Thiers syn­
drome of any importance in the differential diagnosis. 
if indeed they represent true syndromes. 
Cushing·s syndrome is readily differentiated by 
overnight dexamethasone suppression test in most 
patients and by baseline values of glucocorticoids. 
Rarely is virilization of the degree seen with CAH 
present in patients with Cushing's syndrome. Ex­
ogenous administration of virilizing hormones can 
present a problem particularly when the patient does 
not know what she has received. Anabolic steroids 
have been given in wasting diseases, osteoporosis. 
and to improve libido. The differentiation of ovarian 
hyperandrogenic syndromes including Stein­
Leventhal syndrome can generally be made on the 
basis of differential suppression tests employing 
glucocorticoids to suppress the adrenal component 
and combination estrogen-progestogen preparation 
such as Enovid"" E for the ovarian component (41. 
42). True hermaphroditism usually is not much of a 
problem since prepubescent hirsutism is not usually 
evident even though ambiguous genitalia may exist. 
Steroid assays readily differentiate the conditions. 
Occasionally, patients with gonadal dysgenesis with a 
Y stem line (usually) may present with signs or hir­
sutism and clitoromegaly. This has been particularly 
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true of patients with gonadoblastomas or Teter's 
gonocytomas III and IV. Again, steroid assays readi­
ly differentiate the condition. In patients with viriliz­
ing ovarian tumors such as an arrhenoblastoma, 
elevated androgens will not suppress with exogenous 
administration of glucocorticoids. Further, their 
urinary 17-KS are generally not of the magnitude or 
those seen with CAH. 
Summary. Enzymatic defects of adrenal and 
gonadal steroidogenesis have been described, many 
of which lead to amenorrhea and sexual ambiguity. 
Seven patients with congenital adrenal hyperplasia 
are presented who were first diagnosed at times far 
removed from the neonatal period. One such patient 
had dramatic onset of hirsutism, amenorrhea, and 
profound elevation of androgens. After suppression. 
she achieved two pregnancies, delivered. and subse­
quently has gone off therapy and continues to have 
cyclic menses in spite of borderline steroid values. 
The usefulness of a single nighttime long-acting 
glucocorticoid in achieving smooth suppression in 
patients with adrenal hyperplasia appears rational 
and is meeting with success. Diagnosis and monitor­
ing of therapy of such patients has been facilitated 
by the availability of immunoassays for 170H 
progesterone, and testosterone in lieu of urinary 17-
KS, and urinary and plasma pregnanetriol assays. 
Authors' note: Since preparation of this presenta­
tion, Sa reductase deficiency has been described in 
association with male pseudohermaphroditism. 
(Walsh et al, Familial incomplete male pseudo­
hermaphroditism, type 2, decreased dihydrotestoster­
one formation in pseudovaginal perineoscrotal hy­
pospadias, N Engl J Med 291:944-949, 1974). 
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